Are you a medical and health company in Australia –or in an English-speaking country? Do you want to do business with China? If yes to both, then these articles are for you!

I aim to translate and compile latest medical and health news published in Chinese.

First, I translate the original information, which is hand-picked from credible online sources. I then analyse the contents based on insider opinions to provide you with a broader picture.

Little by little, you will have more understanding of Chinese medical and health fields.  When you commercialise your products and services to China, these articles will help you a bit to make informed decisions.

Along the way, if you ever need a bilingual Chinese medical writer or translator, I am here to help!


What are the challenges and joys of doing medical interpreting?

By Amanda Mao, 31-October-2018

Approached by the State Government of Victoria, I had the pleasure to do medical interpreting for 24 Shanghai hospital presidents for their Melbourne visit. Have I missed anything on medical interpreting tips? Do you agree with my opinions? Please comment!


Glenn Cross

Glenn Cross: A Life’s Journey In Commercialising And Exporting Australian Life Sciences

By Amanda Mao, 11-November-2018

Mr Glenn Cross talked about the present and the future of commercialising and exporting Australian life sciences. He also shared valuable lessons and tips based on his life-long experience in the sector. And finally, something about the China healthcare market. This article is based on Glenn’s speech at a recent event co-organised by Melbourne Healthcare Drinks and Australia China Technology Incubator (ACTI).

Rodney Hannington

Chinese Consumer Health Market Insights 

By Amanda Mao, 05-September-2018

Are you an Australian consumer health company keen to expand your brands to China? Would you like to know more about the Chinese Consumer Health Market? Then read on!

Rob ScottLeverging Chinese Healthcare Capital and Resources

By Amanda Mao, 01-March-2018

As another Australian Chinese healthcare commercialisation series, this time the Melbourne HealthCare Drinks event was held on Friday 23rd February, co-organised with ACASE.



The Most Important Policy in New China’s Pharmaceutical Industry

By Amanda Mao, 10-October-2017

On 8th October 2017, the Chinese government issued a ground-breaking policy to encourage innovation on review and approval of drugs and medical devices. On an expanded basis, this document is the official outcome of the CFDA’s draft regulation series on drugs and medical devices.



All You Need to Know about CFDA Joining ICH

By Amanda Mao, 05-July-2017

China Food and Drug Administration (CFDA) was approved as a new regulatory member of the ICH in May/ June 2017. Below we at Acurit Medical Communications translate and edit information from various sources in Chinese to analyse this milestone and its impact on the sector. We especially highlight changes and trends most relevant to international companies.



Fact or Fantasy—New CFDA Draft Regulations on Drugs and Medical Devices

By Amanda Mao, 18-May-2017

On 11 and 12 of May 2017, China Food and Drug Administration (FDA) announced on its official website four new draft regulations on drugs and medical devices. All drafts are currently inviting public comments. We translate the main contents from Chinese into English, focusing on the possible impact on overseas companies.



High-Quality Aged Care Products in Demand in China

By Amanda Mao, 12-Apr-2017

In China, old-age dependency ratio will increase from the current 2.8:1 to 1.3:1 in 2050. On the other hand, the aged care industry still needs to be revitalised. Senile finance, supplies, services and real estate are all in infancy, with huge potential to grow.This, in turn, leaves massive room for aged care businesses overseas to plan their China market entry.



China FDA Adjusts Registration Requirements for Imported Drugs

By Amanda Mao, 20-Mar-2017, updated 11-Oct-2017

The draft regulation was approved by CFDA on 20Jun-2017 and published on 11-Oct-2017, under the title of No. 35 CFDA Degree. There are only minor revisions compared to the original statements. This regulation will bring about far-reaching and profound effects for China pharmaceutical market for imported drugs.